Cloxazolam

Cloxazolam is a benzodiazepine with anxiolytic, sedative/hypnotic, muscle relaxant, and antiepileptic effects. It is marketed in the Argentina, Australia, Portugal, Belgium, Switzerland, Luxembourg, Germany, Taiwan and Japan — mainly for anti-anxiety. The usual dose of cloxazolam in adults is 3-12mg/day for anti-anxiety. Although less commonly noted, it has also been reported as clinically effective in the treatment of depression, schizophrenia, and neurosis. As well, it has also been studied in Japan in doses of 15-30mg/day as an adjunct in the treatment of intractable epilepsy, for which it has demonstrated effectiveness. It is grouped under the following drug class(es): Anxiolytics, Benzodiazepines and Schedule IV controlled substances. Its therapeutic use is listed as antianxiety drugs. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Sepazon and Olcadil. It is listed as a controlled drug substance (Schedule IV). Its PubChem CID is 2816.